BRAF and colorectal carcinoma: This combination is the subject of an open phase I/II study combining trametinib, dabrafenib and panitumumab [44,45] as well as an open-label, phase 3 trial with encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated CRC [46].